Supervisory Board of Sartorius AG extends appointment of the Group´s CEO Dr. Joachim Kreuzburg

Supervisory Board of Sartorius AG extends appointment of the Group´s CEO Dr. Joachim Kreuzburg


At today´s meeting, the Supervisory Board of Sartorius AG unanimously passed the resolution to extend the current appointment of the Group´s CEO, Dr. Joachim Kreuzburg, by another 5-year period to November 10, 2015. Kreuzburg has been a member of the Executive Board since November 11, 2002, and has been the Group´s top executive since May 1, 2003.

Goettingen, December 10, 2009

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.